Evotec has announced a multi-year compound management agreement with Pierre Fabre Laboratories, the second largest private French pharmaceutical group.
Under the terms of the agreement, Evotec will manage Pierre Fabre's compound collection (individual compounds and collection plates) out of its state-of-the-art compound management facility in Toulouse, France. The agreement covers an initial period of five years.
Laurent Audoly, Pierre Fabre Pharmaceuticals R&D Director, commented: "We are delighted to announce this first partnership with Evotec who has become a leading player in the Toulouse drug discovery ecosystem. With its significant expertise in the field of compound management, Evotec will undoubtedly be an important partner for Pierre Fabre to accelerate its discovery and development pace in the fields of oncology, dermatology and CNS."
Dr Mario Polywka, Chief Operating Officer of Evotec, stated: "We welcome Pierre Fabre as another partner who has entrusted their complete compound management needs to our state-of-the-art operation in Toulouse. This collaboration further validates our strategy to establish a state-of-the-art compound management operation out of Toulouse for the European market and cements our position as the world leader in outsourced compound management. We look forward to a long and successful partnership with Pierre Fabre."
No financial details were disclosed.